Viemed Healthcare Achieves Record Q2 2025 Revenues and Expands Guidance

An update from Viemed Healthcare ( (VMD) ) is now available.

Viemed Healthcare reported record net revenues of $63.1 million for the second quarter of 2025, marking a 14.7% increase from the previous year. The company’s net income rose by 115.1% to $3.2 million, and adjusted EBITDA increased by 11.5%. The acquisition of Lehan’s Medical Equipment has allowed Viemed to raise its full-year revenue and adjusted EBITDA guidance, reflecting the company’s strategic growth and strong operational performance. The company also repurchased shares, increased its patient count, and maintained a strong cash position, demonstrating robust financial health and commitment to shareholder value.

The most recent analyst rating on (VMD) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Viemed Healthcare stock, see the VMD Stock Forecast page.

Spark’s Take on VMD Stock

According to Spark, TipRanks’ AI Analyst, VMD is a Outperform.

Viemed Healthcare’s overall score reflects strong financial performance and positive corporate events as key strengths. The bearish technical indicators and modest valuation slightly temper the score. Positive earnings call sentiment and strategic growth initiatives further bolster the company’s prospects.

To see Spark’s full report on VMD stock, click here.

More about Viemed Healthcare

Viemed Healthcare, Inc. is an in-home clinical care provider specializing in post-acute respiratory healthcare equipment and services in the United States. The company focuses on improving the quality of life for patients through compassionate care, particularly in complex respiratory care and women’s health, following its acquisition of Lehan’s Medical Equipment.

Average Trading Volume: 217,154

Technical Sentiment Signal: Sell

Current Market Cap: $249.8M

See more data about VMD stock on TipRanks’ Stock Analysis page.